It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Biogen Inc. (BIIB), which belongs to the Zacks ...

Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi ...

The stock's fall snapped a five-day winning streak.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Citi analyst Geoff Meacham lowered the firm’s price target on Biogen (BIIB) to $160 from $190 and keeps a Neutral rating on the shares. Ahead ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...